Fenova Renal Research Adds to Roster
Frenova Renal Research, a division of Fresenius Medical Care North America (FMCNA) and the contract clinical research services provider dedicated exclusively to renal research, has added an additional location to its roster of manged clinical research sites. The new capacity will enhance Frenova's ability to help clinical research sponsors enroll patients rapidly and streamline clinical trials.
"We look forward to managing this site and working alongside our new partner investigators. Increasing our network of investigators and pool of patients allows our clients to significantly accelerate their clinical trials designed to ultimately better the lives of those living with renal disease," said Kurt Mussina, vice president, FMCNA, and general manager, Frenova Renal Research. "Between 2016 and 2018, we reduced the time from clinical trial agreement to first-patient-first-visit by over 80 percent among the sites we manage."
Frenova's approach to site management reduces administrative burdens, thereby compressing timelines. This provides investigators at sites managed by Frenova the opportunity to enroll patients sooner and with greater efficiency than they would otherwise.
The Las Vegas site of Nevada Kidney Disease and Hypertension Centers contributes 24 physicians, 2,000 ESRD patients, and 15,000 CKD patients to the program.
For more information visit www.FrenovaRenalResearch.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
